LEXINGTON, MA -- (Marketwired) -- 11/09/16 --
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at the Lotte New York Palace Hotel, New York.
Event: Stifel 2016 Healthcare Conference
Date: Wednesday, November 16, 2016
Time: 2:55 PM ET
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
MacDougall Biomedical Communications
Source: Aldeyra Therapeutics
News Provided by Acquire Media